Clinical Trials Logo

Clinical Trial Details — Status: Active, not recruiting

Administrative data

NCT number NCT00396929
Other study ID # TAX-001
Secondary ID 2005-001481-14
Status Active, not recruiting
Phase Phase 3
First received November 7, 2006
Last updated May 15, 2007
Start date August 2005
Est. completion date July 2007

Study information

Verified date May 2007
Source University Hospital Tuebingen
Contact n/a
Is FDA regulated No
Health authority Germany: Federal Institute for Drugs and Medical Devices
Study type Interventional

Clinical Trial Summary

The aim of the study is to examine the efficacy of Paclitaxel injection after a stent implantation in patients with stenosis in native coronary arteries to prevent restenosis in comparision with two admitted therapies.


Description:

The aim of the study is to examine whether in patients with stable or instable Angina pectoris and/or documented myocardial ischemia in the presence of de-novo stenosis in native coronary arteries with a degree of stenosis between 50 % and 99 % an additional local administration of paclitaxel after implantation of a conventional stent is superior to the implantation of a conventional stent alone with respect to late lumen loss (LLL). In case of superiority it will be examined whether an additional local administration of paclitaxel after implantation of a conventional stent is not inferior to the implantation of a paclitaxel-eluting stent with respect to late lumen-luss. Is this the case, superiority will be tested.


Recruitment information / eligibility

Status Active, not recruiting
Enrollment 204
Est. completion date July 2007
Est. primary completion date
Accepts healthy volunteers No
Gender Both
Age group 18 Years to 80 Years
Eligibility Inclusion Criteria:

- age: 18 to 80, males or females

- stable or instable angina pectoris and or/ documented myocardial ischemia

- willingness and ability to adhere to the study conditions

- written informed consent after patient information

- De-novo stenosis of coronary artery with a degree of stenosis between 50% and 99%, that is accessible to PTCA

- Target vessels diameter of at least 2,5 mm and length of lesion below 18 mm

Exclusion Criteria:

- Acute myocardial infarction or still elevated CK/CK-MB after acute myocardial infarction

- known severe arrhythmias that necessitate a long term antiarrhythmic therapy

- pericarditis

- intracardiac thrombus

- Bacterial endocarditis

- Cardiopulmonary reanimation with cardiac massage within the last 6 months

- Thromboembolic accident within the last 6 months

- Severe peripheral arterial occlusive disease, that excludes the use of a 6 French catheter or that requires a special antithrombotic or anticoagulatory regime

- Manifest hyperthyreosis

- Neutrohile granulocytes less than 3000/mm3 and platelets below 100.000 or above 700.000/mm3

- Renal insufficiency with serum creatinine above 1,5 mg/L

- severe systemic hypertension despite antihypertensive medication

- other diseases which might lead to protocol violations or reduce life expectancy

- significant upper intestinal bleeding within the last 6 months

- life expectancy < 1 year

- poor general condition

- Premenopausal women, women who are postmenopausal less than 2 years

- known allergy or hypersensitivity to Paclitaxel, to one of the TAXOL-components, to one of the stent components, to acetylsalicylic acid, heparin, clopidogrel or contrast agent

- Concurrent participation or participation within the last 30 days prior to screening in another drug trial or a trial with a medical device

- absence of written declaration of consent

- inability, to understand sense and purpose of the study or not willing to keep the conditions of the study

- Bifurcation stenosis, ostium stenosis, main stem stenosis ot the target vessel

- visible thrombus in target vessel

- Severely curved or sclerosed target vessel

- complete closure of target vessel

- Severe impairment of left ventricular function with left ventricular ejection fraction of less than 30%

- Patients with expected indication for operative myocardial revascularisation within the next six months

- patients with contraindication for aortocoronary bypass operation,

- patients, who are principally not available for a second coronary angiography 6 months after stent implantation or who have a contraindication for a second coronary angiography

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Treatment


Related Conditions & MeSH terms


Intervention

Drug:
local intracoronary dosis of Paclitaxel


Locations

Country Name City State
Germany Abteilung Kardiologie und Kreislauferkrankungen, Medizinische Universitätsklinik und Poliklinik III, Universitätsklinikum Tübingen Tuebingen

Sponsors (2)

Lead Sponsor Collaborator
University Hospital Tuebingen Acrostak

Country where clinical trial is conducted

Germany, 

Outcome

Type Measure Description Time frame Safety issue
Primary The primary objective is the angiographical determination of the late lumen loss in the stent and/or persistent area, 6 month after stent implantation. week 26 +/- 14 days
Secondary The angiographical determination of the binary restenosis rate, defined as diameter stenosis of at least 50 % in the stent and / or persistent area, 6 months after stent implantation. week 26 +/- 14 days
Secondary The angiographical determination of the degree of stenosis, defined as percentage diameter stenosis in the stent and /or persistent area, 6 months after stent implantation. week 26, +/- 14 days
Secondary Tthe angiographical determination of the minimal lumen diameter in the stent and / or persistent area, 6 months after stent implantation. week 26, +/- 14 days
Secondary The 6 months after stent implantation determined combined endpoint of abrupt and subabrupt closure of the target vessel, target lesion revascularisation and major adverse cardiac events including myocardial infarction and death. week 26, +/-14 days
See also
  Status Clinical Trial Phase
Not yet recruiting NCT06032572 - Evaluation of the Safety and Effectiveness of the VRS100 System in PCI (ESSENCE) N/A
Recruiting NCT05846893 - Drug-Coated Balloon vs. Drug-Eluting Stent for Clinical Outcomes in Patients With Large Coronary Artery Disease N/A
Completed NCT04153006 - Comparison of Fingerstick Versus Venous Sample for Troponin I.
Completed NCT01205776 - EXCEL Clinical Trial N/A
Active, not recruiting NCT04555174 - BIOFLOW-VIII All-comers Orsiro Mission Safety and Performance Registry
Recruiting NCT04582877 - Pressure Guidewire System Multi-center, Prospective, Self-Control, Clinical Trial N/A
Recruiting NCT04390672 - Multivessel TALENT N/A
Recruiting NCT03265535 - Validation of a Single Rest-Stress Imaging Protocol for Myocardial Perfusion Imaging
Not yet recruiting NCT04522583 - Increased CRP Concentrations in Patients Admitted to the Emergency Department With Troponin Elevation Aids to Rule Out Coronary Ischemia
Terminated NCT02407626 - Optimization of Cardioprotection in Diabetic Patients Undergoing Cardiac Surgery N/A
Completed NCT02554006 - Predischarge Bundle to Minimize Negative Impact on Quality of Life of Nuisance Bleedings N/A
Completed NCT02510547 - Comparison of a CrossBoss First Versus Standard Wire Escalation Strategy for Crossing Coronary Chronic Total Occlusion: the "CrossBoss First" Trial Phase 4
Active, not recruiting NCT02189499 - Feasibility Study of the Amaranth Medical FORTITUDE Bioresorbable Drug-Eluting Coronary Stent Phase 2
Completed NCT02264717 - Dan-NICAD - Danish Study of Non-Invasive Diagnostic Testing in Coronary Artery Disease N/A
Completed NCT02197065 - Pilot Study of Atorvastatin for Orthopedic Surgery Patients Phase 2
Recruiting NCT01681381 - Evaluate Safety And Effectiveness Of The Tivoli® DES and The Firebird2® DES For Treatment Coronary Revascularization N/A
Completed NCT01655043 - Absolute Quantification of Coronary Flow Reserve by Stress Perfusion MRI Phase 2
Completed NCT01679886 - Comparison of Rubidium PET and SPECT With CZT Crystals for Detection of Myocardial Ischemia in Overweighed Patients and Women N/A
Terminated NCT01892917 - BIOFLOW-III Hungary Satellite Registry N/A
Completed NCT02707445 - Genotyping Influences Outcome of Coronary Artery Stenting N/A